Aurobindo Pharma, a leading pharmaceutical company, has announced the conclusion of a United States Food and Drug Administration (US FDA) audit at its Unit-II formulation manufacturing facility located in Bhiwadi, Rajasthan. The inspection, which took place from April 25, 2024, to May 3, 2024, resulted in the identification of nine observations by the regulatory authority.
According to Aurobindo Pharma, the observations made by the US FDA are procedural in nature and will be addressed within the stipulated time frame. The company’s statement underscores its commitment to ensuring compliance with regulatory standards and addressing any issues identified during inspections promptly and effectively.
Aurobindo Pharma is primarily involved in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company has a robust presence in both domestic and international markets, with a focus on delivering high-quality, affordable healthcare solutions to patients worldwide.
In its recent financial performance, Aurobindo Pharma reported a significant increase in consolidated net profit, registering a 90.58% jump to Rs 936.29 crore, accompanied by a 13.82% rise in revenue from operations to Rs 7,271.23 crore in the third quarter of FY24 compared to the same period in the previous fiscal year.
Despite the audit findings, Aurobindo Pharma’s stock remained resilient, with the scrip experiencing a marginal decline of 0.10% to close at Rs 1152.70 on the Bombay Stock Exchange (BSE) on Friday. The company’s strong financial performance and ongoing efforts to maintain regulatory compliance position it for continued growth and success in the pharmaceutical industry.
